
| 2019 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Total Project Funding per Partner: | > 1000 |
| Total Number of Projects: | > 1000 |
| 2016 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
| 2015 | |
| Criterium: | Position: |
| Overall Score: | > 1000 |
| Networking Rank (Reputation): | > 1000 |
Total number of projects: 5
As coordinator: 0
As participant: 5
Sole participant: 0
Coordinator / Participant Ratio: 0*
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2019 | 0 | 14.839.774 | 718.845 | 1 | ||
| 2017 | 0 | 5.934.086 | 301.870 | 1 | ||
| 2016 | 0 | 12.607.357 | 389.875 | 2 | ||
| 2015 | 0 | 5.913.080 | 142.282 | 1 | ||
Total number of partners: 56
Partner loyalty:
Frequent Partner: (> 2 projects): 3
Rare Partner: 53
Frequent / Rare Partner Ratio: 0.06
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2019-01-01 | CardioReGenix: Development of Next-Generation Gene Therapies for Cardiovascular Disease | CardioReGenix | participant | 14.839.774 | 13 |
| 2017-01-01 | Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory anginaA phase II randomized, double-blinded, placebo-controlled study | ReGenHeart | participant | 5.934.086 | 9 |
| 2016-01-01 | Development of a systems biomedicine approach for risk identification, prevention and treatment of type 2 diabetes | T2DSystems | participant | 5.998.603 | 12 |
| 2016-01-01 | Boost Brittle Bones Before Birth | BOOSTB4 | participant | 6.608.755 | 13 |
| 2015-05-01 | Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease. | CARBALIVE | participant | 5.913.080 | 14 |